Vitamin D supplementation in breastfed infants from Montréal, Canada: 25-hydroxyvitamin D and bone health effects from a follow-up study at 3 years of age.

Plain-language guide to PMID 26968165 (2016): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 87 infants.

Key Facts

PMID: 26968165
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Year: 2016
Study type: Randomized Controlled Trial
Authors: Gallo S et al. (8 authors)
DOI: 10.1007/s00198-016-3549-z

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This study provides important data to inform pediatric public health recommendations for vitamin D.

Who Took Part

The study group was 87 infants.

PubMed indexes the participants as infants and young children, both men and women.

This was a double-blind randomized trial of 132, 1-month-old healthy, breastfed infants from Montréal, Canada, between 2007 and 2010.

How the Study Was Run

The design is described as randomized and double-blind.

The infants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the infants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Lumbar spine vertebrae 1-4 (LS) bone mineral density (BMD), LS and whole body bone mineral content (BMC), and mineral accretion were measured by dual-energy x-ray absorptiometry at 3 years.

What Was Measured

Topics PubMed links to this paper include Bone Density, Breast Feeding, Canada, Cholecalciferol, Dietary Supplements and Vitamin D.

Author keywords: 25-hydroxyvitamin D, Bone mineral, Bone mineral accretion, Dual-energy x-ray absorptiometry, Infants and Pediatrics.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 87 infants.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.